Credits Available: 4.75 AMA PRA Category 1 Credit™/ MOC Points

Description: This curriculum examines the latest advancements in antibody-drug conjugate (ADC) therapy for metastatic triple-negative breast cancer (mTNBC) and HER2-low (HER+/HER2-) breast cancer. It provides insights into mechanisms of action, emerging clinical data, and strategies for integrating ADCs into treatment regimens to improve patient outcomes. Expert-led discussions and case-based learning will support clinicians in individualizing therapy and addressing real-world challenges in ADC use.

CME/CE Accreditation Information

If you already have a Gather-ed account, please login

Email:
Password:

Register

Step 1 of 3

This program is intended for:
Target Professions: DO, MD, Nurse Practitioner, Physician Associate/Assistant
Target Specialties: Oncology

Kirollos Hanna

M Health Fairview and Mayo Clinic College of Medicine
Oncology Pharmacy Manager and Assistant Professor

Dr. Hanna is board certified by the Board of Pharmacy Specialties in Oncology Pharmacy and Pharmacotherapy. He received his doctorate of pharmacy from Florida A&M University, completed his general residency at St. Thomas Hospital, Nashville, TN and his oncology residency at St. Luke's Mountain States Tumor Institute, Boise, ID. He is currently an Assistant Professor of Pharmacy at the Mayo Clinic College of Medicine and the Director of Pharmacy at Minnesota Oncology.

Dr. Hanna’s research interests are focused on outcome measures for patients with rare diseases, B-cell malignancies, and genitourinary cancers. He has published over a dozen peer-reviewed manuscripts in various journals including Pharmacotherapy, AJHP, JOPP, AJMC and JHOP. He is a member of the Executive Council for the National Community Oncology Dispensing Association (NCODA) and is an active member of numerous professional organizations including ACCC, HOPA, and ACCP.